Kirk A Frey, MD
University of Michigan Rogel Cancer Center · University of Michigan
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kirk A Frey, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:54 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07682649 · Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate CancerUniversity of Michigan Rogel Cancer Center · not yet recruiting · Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 · principal investigator
- Ph1NCT02844179 · (+)-Alpha-Dihydrotetrabenazine Phase IKirk A. Frey · completed · Healthy Subjects · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Enhancing radioligand therapy for prostate cancer with biomarker and dosimetry guided personalizationR01CA289631 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI YUNI K DEWARAJA · fiscal years 2024 to 2025Named on NCT07682649
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.